Cetuximab
A novel combination therapy of garsorasib and cetuximab for KRAS G12C mutated colorectal cancer patients
Anika Sharma
Dā1553 is a small-molecule inhibitor designed to selectively target KRAS G12C and is currently undergoing Phase II clinical trials. It ...
Companion Diagnostic for Encorafenib + Cetuximab in BRAF V600E alteration in mCRC Receives FDA Approval
SG Tylor
Source – Foundation Medicine In order to identify patients with metastatic colorectal cancer (mCRC) who could be candidates to receive ...
